Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial.
Authors: Lipton et al.
Neurology. 2022 Nov 17:10.1212/WNL.0000000000201568. Online ahead of print.
TRIAL REGISTRATION: ClinicalTrials.gov NCT03777059. Submitted: 12/13/2018; First patient enrolled: 12/14/2018. https://clinicaltrials.gov/ct2/show/NCT03777059 CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that daily atogepant is associated with improvements in health-related quality of life measures in patients with 4-14 migraine days/month.
Share this article
Sign Up For An MSC Newsletter
Sign Up for MSC Content Alerts!
Interested in receiving notifications about new MSC content? Then sign up for our content alerts and be the first to know about our latest articles, literature recaps and more!